Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
US12274793B2 · kind B2 · utility
0Cited by
63References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 10, 2024 |
| Grant date | Apr 15, 2025 |
| Priority date | — |
| Expiry date | Oct 10, 2044 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.